Skip to main content
SpringerLink
Log in

Cutaneous Anaplastic Large-Cell Lymphoma Should be Evaluated for Systemic Involvement Regardless of ALK-1 Status

Case Reports and Review of Literature

  • Case Reports
  • Cutaneous Anaplastic Large-Cell Lymphoma
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Anaplastic large-cell lymphoma (ALCL) is a lymphoma that expresses CD30. Cutaneous ALCL presents either as primary cutaneous disease or as secondary skin involvement due to the systemic disease. Herein, we describe two patients who presented to dermatology for evaluation of skin lesions diagnosed by non-dermatologists as a cutaneous abscess and lupus erythematosus, respectively. Upon investigation by a team of medical dermatologists and dermatopathologists, systemic ALCL with secondary skin involvement was discovered in both patients. The majority of cases of systemic ALCL with cutaneous involvement express anaplastic lymphoma kinase-1 (ALK-1), and are associated with a more favorable prognosis than ALK-1-negative cases. However, cutaneous ALCL regardless of ALK-1 status may be secondary to systemic lymphoma. This article stresses the importance of dermatologists being aware of the diagnosis of systemic lymphoma based on cutaneous findings, and being aggressive in initiating appropriate diagnostic testing. Primary cutaneous ALCL and systemic ALCL are reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848–58

    PubMed  CAS  Google Scholar 

  2. Jaffe ES, Harris NL, Stein H, et al. Pathology and genetics of tumours of haematopoietic and lymphoid tissues: World Health Organization Classification of Tumours. Lyon: IARC Press, 2001

    Google Scholar 

  3. Savage KJ, Harris NL, Vose JM, et al. ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-cell Lymphoma Project. Blood 2008; 111 (12): 5496–504

    Article  PubMed  CAS  Google Scholar 

  4. Stein H, Foss H, Durkop H, et al. CD30+ anaplastic large cell lymphoma: a review of its histologic, genetic, and clinical features. Blood 2000 Dec 1; 96 (12): 3681–95

  5. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al. ALK-negative systemic anaplastic large cell lymphoma: differential diagnosis and prognostic aspects: a review. J Pathol 2003; 200: 4–15

    Article  PubMed  Google Scholar 

  6. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 1994; 263 (5151): 1281–4

    Article  PubMed  CAS  Google Scholar 

  7. Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinicopathological findings and outcome. Blood 1999; 93 (8): 2697–706

    PubMed  CAS  Google Scholar 

  8. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the chimeric protein p80 NPM/ALK: a distinct clinicopathologic entity. Blood 1995; 86: 1954–60

    PubMed  CAS  Google Scholar 

  9. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000 Jun 15; 95 (12): 3653–61

  10. Willemze R, Meijer C. Primary cutaneous CD30-positive lymphoproliferative disorders. Hematol Oncol Clin N Am 2003; 17: 1319–32

    Article  Google Scholar 

  11. Paulli M, Berti E, Rosso R, et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin: clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol 1995; 13 (6): 1343–54

    PubMed  CAS  Google Scholar 

  12. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–92

    PubMed  CAS  Google Scholar 

  13. Foss H, Anagnostopoulos I, Araujo I, et al. Anaplastic large cell lymphoma of T-cell and null-cell phenotype express cytotoxic molecules. Blood 1996; 88: 4005–11

    PubMed  CAS  Google Scholar 

  14. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK(+) lymphoma: a single disease with a broad spectrum of morphology. Blood 1998; 91: 2076–84

    PubMed  CAS  Google Scholar 

  15. Kinney MC, Collins RD, Greer JP, et al. A small cell predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. Am J Surg Pathol 1993; 17: 859–68

    Article  PubMed  CAS  Google Scholar 

  16. Pileri S, Falini B, Delsol G, et al. Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1+ with a high content of reactive histiocytes). Histopathology 1990; 16: 383–91

    Article  PubMed  CAS  Google Scholar 

  17. Jaffe ES, Harris NL, Diebold J, et al. World Health Organization classification of lymphomas: a work in progress. Ann Oncol 1998; 9 Suppl. 5: S25–30

    Article  Google Scholar 

  18. Bayle C, Charpentier A, Duchayne E, et al. Leukaemic presentation of small cell variant anaplastic large cell lymphoma: report of four cases. B J Haematol 1999; 104: 680–8

    Article  CAS  Google Scholar 

  19. Fornari A, Piva R, Chiarle R, et al. Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? Hematol Oncol 2009; 27: 161–70

    Article  PubMed  CAS  Google Scholar 

  20. Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8: 11–23

    Article  PubMed  CAS  Google Scholar 

  21. Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997; 14: 439–49

    Article  PubMed  CAS  Google Scholar 

  22. Souttou B, Carvalho NB, Raulais D, et al. Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through mitogen-activated protein kinase pathway. J Biol Chem 2001; 276 (12): 9526–31

    Article  PubMed  CAS  Google Scholar 

  23. Delsol G, Lamant L, Mariame B, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 1997; 89: 1483

    PubMed  CAS  Google Scholar 

  24. Grewal JS, Krauss JC, Schnitzer B, et al. Highly aggressive ALK-positive anaplastic large cell lymphoma with a leukemic phase and multi-organ involvement: a report of three cases and a review of the literature. Ann Hematol 2007; 86: 499–508

    Article  PubMed  Google Scholar 

  25. ten Berge RL, Dukers DF, Oudejans JJ, et al. Adverse effects of activated cytotoxic T-lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma. Blood 1999; 93: 2688–96

    PubMed  Google Scholar 

  26. Onciu M, Behm F, Raimondi S, et al. ALK positive anaplastic large cell lymphoma with leukemic peripheral blood involvement is a clinicopathologic entity with an unfavorable prognosis: report of three cases and review of the literature. Am J Clin Pathol 2003; 120: 617–25

    Article  PubMed  Google Scholar 

  27. Kong SY, Cho HJ, Suk JH, et al. A novel complex t(2;5;13)(p23;q35;q14) in small cell variant type of anaplastic large cell lymphoma with peripheral involvement. Cancer Genet Cytogenet 2003; 154: 183–5

    Article  Google Scholar 

  28. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007; 25 (19): 2764–9

    Article  PubMed  CAS  Google Scholar 

  29. Novitzky N, Thomas V. Allogeneic stem cell transplantation with T-cell depleted grafts for lymphoproliferative malignancies. Biol Blood Marrow Transplant 2007; 13 (1): 107–15

    Article  PubMed  CAS  Google Scholar 

  30. Rijlaarsdam JU, Huijgens PC, Beljaards RC, et al. Oral etoposide in the treatment of cutaneous large-cell lymphomas: a preliminary report of four cases. Br J Dermatol 1992; 127: 524–8

    Article  PubMed  CAS  Google Scholar 

  31. Chou WC, Su IJ, Tien HF, et al. Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese patients with Ki-1 anaplastic large cell lymphoma: special emphasis on the tumor response to 13-cis-retinoic acid. Cancer 1996; 78: 1805–12

    Article  PubMed  CAS  Google Scholar 

  32. French LE, Shapiro M, Junkins-Hopkins JM, et al. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy. J Am Acad Dermatol 2001; 45: 914–8

    Article  PubMed  CAS  Google Scholar 

  33. Didona B, Benucci R, Amerio P, et al. Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara). Br J Dermatol 2004; 150 (6): 1198–201

    Article  PubMed  CAS  Google Scholar 

  34. Shehan JM, Kalaaji AN, Markovic SN, et al. Management of multifocal primary cutaneous CD30+ anaplastic large cell lymphoma. J Am Acad Dermatol 2004; 51 (1): 103–10

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Pittsburgh Physicians, 200 Lothrop Street, Presbyterian South Tower - Suite 3880, 15213, Pittsburgh, Pennsylvania, USA

    Sherry Yang, Pooja Khera, Christina Wahlgren, Jon Ho, Drazen Jukic, Larissa Geskin &  Joseph C. English III

Authors
  1. Sherry Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pooja Khera
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christina Wahlgren
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jon Ho
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Drazen Jukic
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Larissa Geskin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Joseph C. English III
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, S., Khera, P., Wahlgren, C. et al. Cutaneous Anaplastic Large-Cell Lymphoma Should be Evaluated for Systemic Involvement Regardless of ALK-1 Status. Am J Clin Dermatol 12, 203–209 (2011). https://doi.org/10.2165/11537520-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11537520-000000000-00000

Keywords

Search

Navigation